Invitae Gets CE-IVD Mark for Its Cancer Testing Kits

February 23, 2022

Medical genetics company Invitae has received a CE-IVD mark for its FusionPlex Dx and LiquidPlex Dx molecular tests for nonsmall-cell lung cancer.

FusionPlex Dx provides genomic profiling for patients with solid malignant growths while LiquidPlex Dx can identify circulating tumor DNA from a liquid biopsy, to identify patients who may benefit from a targeted therapy.

The panels are intended to be used on Illumina's next-generation sequencing platforms for in-vitro diagnostic testing. The company expects the diagnostic tests to be in high demand in Europe, where most of the molecular testing is performed in decentralized hospital settings.

View today's stories